
    <rss version="2.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd">
      <channel>
        <title>Articles tagged with Cardiovascular from Medical Marketing and Media</title>
        <link>http://www.mmm-online.com/cardiovascular/topic/19669/</link>
        <description>Articles tagged with Cardiovascular from Medical Marketing and Media</description>
        <itunes:author>MMM</itunes:author>
        <itunes:subtitle></itunes:subtitle>
        <itunes:summary></itunes:summary>
        <itunes:owner>
            <itunes:name></itunes:name>
            <itunes:email>mmmsubs@haymarketmedia.com</itunes:email>
        </itunes:owner>
        <itunes:category text="BUSINESS">
            <itunes:category text="BUSINESS NEWS" /> 
        </itunes:category> 
        <itunes:image href='http://media.haymarketmedia.com/images/32/MMM_logo_28402_31022.gif'></itunes:image>
        <itunes:explicit>no</itunes:explicit>
  
        <item>
          <title>Business briefs: Medtronic, AMA, Komen, GSK, Lilly, AZN</title>
          <description>Studies undercut Medtronic spine treatment benefit, AMA wars over obesity classification, Komen gets a new CEO, GSK offloads thrombosis meds, Lilly gains diabetes treatment, AZN chooses new site</description>
          <link>http://www.mmm-online.com/business-briefs-medtronic-ama-komen-gsk-lilly-azn/article/299240/</link>
          <pubDate>Tue, 18 Jun 2013 16:50:13 GMT</pubDate>
          <itunes:summary>Studies undercut Medtronic spine treatment benefit, AMA wars over obesity classification, Komen gets a new CEO, GSK offloads thrombosis meds, Lilly gains diabetes treatment, AZN chooses new site</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Business briefs: Boehringer Ingelheim, Teva, Medicare</title>
          <description>Good and bad news about Pradaxa; Plan B decision not deemed a big threat to Teva&apos;s sales; Study says Medicare patients more likely to receive brand-name medications than VA patients</description>
          <link>http://www.mmm-online.com/business-briefs-boehringer-ingelheim-teva-medicare/article/298497/</link>
          <pubDate>Wed, 12 Jun 2013 17:03:59 GMT</pubDate>
          <itunes:summary>Good and bad news about Pradaxa; Plan B decision not deemed a big threat to Teva&apos;s sales; Study says Medicare patients more likely to receive brand-name medications than VA patients</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Weight-loss category expands by one</title>
          <description>Eisai brings Belivq to 20,000 US pharmacies, along with 200 sales reps and a physician marketing push.</description>
          <link>http://www.mmm-online.com/weight-loss-category-expands-by-one/article/297241/</link>
          <pubDate>Tue, 11 Jun 2013 15:23:45 GMT</pubDate>
          <itunes:summary>Eisai brings Belivq to 20,000 US pharmacies, along with 200 sales reps and a physician marketing push.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>AstraZeneca buys respiratory specialist Pearl Therapeutics</title>
          <description>The drug maker eases the burden on its Symbicort franchise by scooping up Pearl for $510 million.</description>
          <link>http://www.mmm-online.com/astrazeneca-buys-respiratory-specialist-pearl-therapeutics/article/297134/</link>
          <pubDate>Mon, 10 Jun 2013 17:00:12 GMT</pubDate>
          <itunes:summary>The drug maker eases the burden on its Symbicort franchise by scooping up Pearl for $510 million.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Amarin launches unbranded triglyceride info site</title>
          <description>The launch is part of its overall marketing program, which includes deploying 275 sales reps to market the drug which officially launched in January.</description>
          <link>http://www.mmm-online.com/amarin-launches-unbranded-triglyceride-info-site/article/296612/</link>
          <pubDate>Thu, 06 Jun 2013 16:20:43 GMT</pubDate>
          <itunes:summary>The launch is part of its overall marketing program, which includes deploying 275 sales reps to market the drug which officially launched in January.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Business briefs: AbbVie, AstraZeneca, Valeant, Merck, Novo Nordisk</title>
          <description>AbbVie&apos;s Niaspan pricing gets a hard look; AstraZeneca buys up heart drug and company; Valeant expands eye care portfolio with B&amp;L; Merck halts Parkinson&apos;s study; Novo explores liraglutide weight loss results.</description>
          <link>http://www.mmm-online.com/business-briefs-abbvie-astrazeneca-valeant-merck-novo-nordisk/article/295160/</link>
          <pubDate>Tue, 28 May 2013 16:55:44 GMT</pubDate>
          <itunes:summary>AbbVie&apos;s Niaspan pricing gets a hard look; AstraZeneca buys up heart drug and company; Valeant expands eye care portfolio with B&amp;L; Merck halts Parkinson&apos;s study; Novo explores liraglutide weight loss results.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Mayo device helps monitor heart patients from afar</title>
          <description>Device maker Preventice says the peel-and-stick monitor has the potential to go beyond the critical care market and into the sports world.</description>
          <link>http://www.mmm-online.com/mayo-device-helps-monitor-heart-patients-from-afar/article/294386/</link>
          <pubDate>Wed, 22 May 2013 14:59:55 GMT</pubDate>
          <itunes:summary>Device maker Preventice says the peel-and-stick monitor has the potential to go beyond the critical care market and into the sports world.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Studies show cost doesn&apos;t drive everything</title>
          <description>Two studies show that it&apos;s not enough to focus on cost to alter healthcare.</description>
          <link>http://www.mmm-online.com/studies-show-cost-doesnt-drive-everything/article/289870/</link>
          <pubDate>Mon, 22 Apr 2013 15:39:42 GMT</pubDate>
          <itunes:summary>Two studies show that it&apos;s not enough to focus on cost to alter healthcare.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Success in emerging markets hinges on broad network</title>
          <description>Execs told Booz &amp; Co researchers that the relationships web in emerging markets needs to be deeper than one-on-one sales pitches.</description>
          <link>http://www.mmm-online.com/success-in-emerging-markets-hinges-on-broad-network/article/287295/</link>
          <pubDate>Wed, 03 Apr 2013 14:50:50 GMT</pubDate>
          <itunes:summary>Execs told Booz &amp; Co researchers that the relationships web in emerging markets needs to be deeper than one-on-one sales pitches.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Business briefs: United Concordia, FDA</title>
          <description>United Concordia finds a way to slash healthcare costs for $4,000 a year, and FDA goes on tour to promote tighter compounding oversight</description>
          <link>http://www.mmm-online.com/business-briefs-united-concordia-fda/article/286250/</link>
          <pubDate>Wed, 27 Mar 2013 16:00:20 GMT</pubDate>
          <itunes:summary>United Concordia finds a way to slash healthcare costs for $4,000 a year, and FDA goes on tour to promote tighter compounding oversight</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
      </channel>
    </rss>  
  